Citations

Clear

246 citation(s) found for "Study, Alfa".

α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
Xiong, Chengjie , Quadalti, Corinne , Rossi, Marcello , Vöglein, Jonathan , Bernhardt, Alexander , Perrin, Richard J. , Preische, Oliver, Hofmann, Anna, Cairns, Nigel J. , Franklin, Erin , Chrem, Patricio, Berman, Sarah , Chhatwal, Jasmeer P. , Daniels, Alisha , Day, Gregory S. , Ryan, Natalie S. , Goate, Alison , Gordon, Brian A. , Huey, Edward D. , Masters, Colin L. , Morris, John C. , Noble, James M. , Roh, Jee Hoon , Frosch, Matthew P. , Sánchez‐Valle, Raquel , Supnet, Charlene , Network, Dominantly Inherited Alzheimer, Xiong, Chengjie , Parchi, Piero , Gordon, Brian A , Sánchez-Valle, Raquel , Day, Gregory S , Masters, Colin L , Vöglein, Jonathan , Morris, John C , Roh, Jee Hoon , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Baiardi, Simone , Iranzo, Alex , Jucker, Mathias , Höglinger, Günter U. , Cruchaga, Carlos , Ibanez, Laura , Karch, Celeste M. , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , Renton, Alan , Keene, C. Dirk , McLean, Catriona , Schofield, Peter R. , Xiong, Chengjie , Giese, Armin , Hansson, Oskar , Bateman, Randall J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | April 26, 2024 | Volume: 20 | Issue: 6 | Pages: 4351-4365

10.1002/alz.13818 | PMID 38666355 Get It

AbstractINTRODUCTIONAmyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.METHODSUsing an α‐synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo.RESULTSNo asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α‐synuclein seeding activity in CSF in vivo.DISCUSSIONResults suggest that in ADAD LBP occurs later than AD pathology and often as amygdala‐ or olfactory‐predominant LBP, for which CSF α‐synuclein SAA has low sensitivity.Highlights Cerebrospinal fluid (CSF) real‐time quaking‐induced conversion (RT‐QuIC) detects misfolded α‐synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT‐QuIC does not detect α‐synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala‐predominant variants. LBP develops late in the disease course in ADAD. CSF α‐synuclein RT‐QuIC has low sensitivity for focal, low‐burden LBP.
Abstract 1793: Transmembrane serine protease TMPRSS11B promotes tumorigenesis in lung squamous cell carcinoma through enhanced lactate export and modulation of the tumor microenvironment
Updegraff, Barrett L., Zhu, Jingfei , Thomas, Lisa , Barnfather, Isabel , Hwang, Tae Hyun , O’Donnell, Kathryn A. , Sunil, Hari Shankar , Evers, Bret M. , Clemenceau, Jean R. , Minna, John Dorrance , DeBerardinis, Ralph J. , Oliver, Trudy G.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1793-1793

10.1158/1538-7445.am2024-1793 Get It

Abstract Lung cancer is the leading cause of cancer-related deaths worldwide. Existing therapeutic options have limited efficacy, underscoring the critical need for the identification of new actionable therapeutic targets. We previously identified the Transmembrane Serine Protease TMPRSS11B as a novel gene that promotes the transformation of human bronchial epithelial cells in vitro and induces tumorigenesis in vivo. TMPRSS11B promotes extracellular release of Basigin, an obligate chaperone of the lactate monocarboxylate transporters MCT1/4, enhancing lactate export and glycolytic metabolism, and thereby promoting tumorigenesis. Importantly, TMPRSS11B is frequently overexpressed in human lung squamous cell cancers (LSCC) and high expression is associated with poor patient survival. Moreover, as a cell surface protein and enzyme, TMPRSS11B represents a tractable target for therapeutic intervention. To investigate whether TMPRSS11B activity impacts the host immune system and the tumor microenvironment (TME), we evaluated the effect of Tmprss11b depletion in a syngeneic LSCC mouse model, KLN205. Tmprss11b loss of function in KLN205 LSCC cells significantly reduced tumor burden in immunocompetent mice and triggered an accumulation of CD4+ T cells. We are currently extending these studies by investigating the effect of Tmprss11b loss of function using CRISPR/Cas9 editing in the Rosa26LSL-Sox2-IRES-GFP; Nkx2-1 fl/fl; Lkb1fl/fl (SNL) mouse model of LSCC. Tumor burden analysis and pH-sensitive fluorescent imaging are ongoing to assess changes in lactate accumulation. Moreover, RNA FISH analysis and spatial transcriptomics revealed that Tmprss11b expression is highly enriched in lung squamous tumors compared to lung adenocarcinomas and normal lung in SNL mice. Spatial analysis of the transcriptome is currently ongoing to assess the effects of Tmprss11b expression on the TME. Collectively, these studies will elucidate the molecular mechanisms through which TMPRSS11B promotes tumor growth and alters the tumor microenvironment in LSCC. Citation Format: Hari Shankar Sunil, Barrett L. Updegraff, Jingfei Zhu, Lisa Thomas, Bret M. Evers, Jean R. Clemenceau, Isabel Barnfather, John D. Minna, Ralph J. Deberardinis, Trudy G. Oliver, Tae Hyun Hwang, Kathryn A. O'Donnell. Transmembrane serine protease TMPRSS11B promotes tumorigenesis in lung squamous cell carcinoma through enhanced lactate export and modulation of the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1793.
The past, present, and future of the brain imaging data structure (BIDS)
Markiewicz, Christopher J. , Bansal, Shashank , Bénar, Christian , Bertazzoli, Giacomo , Bhogawar, Suyash , Blair, Ross , Brooks, Teon L , Calhoun, Vince D. , Castelli, Filippo Maria , D’Ambrosio, Sasha , Hollander, Gilles de , Vega, Alejandro de la , Delorme, Arnaud , Earl, Eric , Feingold, Franklin , Flandin, Guillaume, Galassi, Anthony , Gallitto, Giuseppe , Ganz, Melanie , Gholam, James , Ghosh, Satrajit , Guidali, Giacomo , Handwerker, Daniel A. , Hardcastle, Nell , Innis, Robert B. , Ioanas, Horea-Ioan , Jahn, Andrew , Karakuzu, Agâh , Kincses, Bálint , Lau, Jonathan C. , Li, Xiangrui , Meisler, Steven L. , Mikkelsen, Mark E. , Nichols, Thomas E. , Ort, Eduard , Park, Patrick J., Pawlik, Mateusz , Pestilli, Franco , Pollonini, Luca , Rizzo, Gaia , Robbins, Kay A. , Rockhill, Alexander P. , Rogers, Christine , Rokem, Ariel , Rorden, Chris , Routier, Alexandre , Saborit-Torres, Jose Manuel , Schirner, Michael , Smith, Robert E. , Sprenger, Julia , Szinte, Martin , Thomas, Adam G. , Torabian, Sajjad, Voytek, Bradley , Calhoun, Vince D. , Poldrack, Russell A. , Appelhoff, Stefan , Ashar, Yoni K. , Auer, Tibor , Baillet, Sylvain , Beltrachini, Leandro , Bortoletto, Marta , Boudreau, Mathieu , Clement, Patricia , Cohen, Alexander L. , Cohen-Adad, Julien , Iglesia-Vayá, María de la , Devinsky, Orrin , Draschkow, Dejan , Duff, Eugene Paul , DuPré, Elizabeth , Estéban, Oscar , Gau, Rémi , Ghosh, Satrajit S , Giacomel, Alessio , Gillman, Ashley , Gleeson, Padraig , Gramfort, Alexandre , Guay, Samuel , Halchenko, Yaroslav O. , Herholz, Peer , Hermes, Dora , Honey, Christopher John , Keator, David B. , Kiar, Gregory , Laird, Angela R. , Lazari, Alberto , Legarreta, Jon Haitz , Li, Adam , Love, Bradley C. , Lu, Hanzhang , Marcantoni, Eleonora , Maumet, Camille , Mazzamuto, Giacomo , Mutsaerts, Henk , Nikolaidis, Aki , Nilsonne, Gustav , Niso, Guiomar , Nørgaard, Martin Agge , Okell, Thomas W. , Oostenveld, Robert , Pernet, Cyril R , Petr, Jan , Phillips, Christophe L. M. , Poline, Jean‐Baptiste , Raamana, Pradeep Reddy , Ritter, Petra , Salo, Taylor , Spisák, Tamás , Swann, Nicole C. , Takerkart, Sylvain , Thirion, Bertrand , Varoquaux, Gaël , Welzel, Julius , Wilson, Martin , Yarkoni, Tal , Gorgolewski, Krzysztof J.

Mayo Clinic

Imaging Neuroscience | February 20, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00103 | PMID 39308505 Get It

Abstract The Brain Imaging Data Structure (BIDS) is a community-driven standard for the organization of data and metadata from a growing range of neuroscience modalities. This paper is meant as a history of how the standard has developed and grown over time. We outline the principles behind the project, the mechanisms by which it has been extended, and some of the challenges being addressed as it evolves. We also discuss the lessons learned through the project, with the aim of enabling researchers in other domains to learn from the success of BIDS.
Genome-wide association analysis identifies PLA2G4C as a susceptibility locus for Multiple System Atrophy
Tsuji, Shoji , Nakahara, Yasuo , Mitsui, Jun , Date, Hidetoshi, Porto, Kristine Joyce L. , Hyashi, Y., Kusakabe, Yoshio , Matsukawa, Takashi , Ishiura, Hiroyuki , Yasuda, Tsutomu , Goto, Jun , Ichikawa, Yaeko, Momose, Yoshio, Takahashi, Yuji , Ohta, Rikifumi , Yoshimura, Jun , Gustavsson, Emil K. , Christy, Darren, Maczis, Melisa, Gu, Weihong, Scholz, Sonja W. , Houlden, Henry , Sasaki, Hidenao , Kikuchi, Akio , Hara, Kenju , Kakita, Akiyoshi , Yamada, Mitsunori , Nishizawa, Masatoyo , Ito, Mizuki , Sobue, Gen , Ishikawa, Kinya , Mizusawa, Hidehiro, Kanai, Kazuaki , Arai, Kimihito , Koyano, Shigeru , Kuroiwa, Yoshiyuki , Hasegawa, Kazuko, Yuasa, Tatsuhiko, Yasui, Kenichi, Ito, Hijiri, Izumi, Yuishin , Kaji, Ryuji , Kato, Takeo , Kusunoki, Susumu , Osaki, Yasushi , Horiuchi, Masahiro , Yamamoto, Ken , Shimada, Mihoko , Miyagawa, Taku , Nishida, Nao , Tokunaga, Katsushi , Filla, Alessandro , Klockgether, Thomas , Wuellner, Ullrich, Kukull, Walter A. , Masliah, Eliezer , Low, Phillip A. , Sandroni, Paola , Ozelius, Laurie J. , Trojanowski, John Q. , Scholz, Sonja W , Houlden, Henry , Yamashita, Atsushi , Yasuda, Tsutomu, Iwata, Atsushi , Toda, Tatsushi , Morishita, Shinichi , Kim, Han‐Joon , Park, Sung Sup , Zhang, Jin , Chelban, Viorica , Mok, Kin Ying , Yabe, Ichiro , Matsushima, Masaaki , Takashima, Hiroshi , Aoki, Masashi , Takahashi, Hitoshi , Onodera, Osamu , Watanabe, Hirohisa , Kuwabara, Satoshi , Nakashima, Kenji , Horiuchi, Masahiro, Kawai, Yosuke , Dürr, Alexandra , Brice, Alexis , Tanner, Caroline M. , Lee, Virginia M.‐Y. , Foroud, Tatiana , Farrer, Matthew J.

Mayo Clinic

No container title available | February 6, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3461290/v1 Get It

Abstract To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies in Japanese, Korean, Chinese, European, and North American samples. In the GWAS stage, rs2303744 on chromosome 19 showed a suggestive association (P = 6.5 × 10− 7) that was replicated in additional Japanese samples (P = 2.9 × 10− 6, odds ratio (OR) = 1.58; 95% confidence interval (CI), 1.30–1.91), and then confirmed as highly significant in a meta-analysis of East Asian population data (P = 5.0 × 10− 15, OR = 1.49; 95% CI 1.35–1.65). The association of rs2303744 with MSA remained significant in combined European/North American samples (P = 0.017, OR = 1.12; 95% CI 1.02–1.23) despite allele frequencies being quite different between these populations. rs2303744 leads to an amino acid substitution in PLA2G4C that encodes the cPLA2γ lysophospholipase/transacylase. The cPLA2γ-Ile143 isoform encoded by the MSA risk allele has significantly decreased transacylase activity compared with the alternate cPLA2γ-Val143 isoform, and may perturb membrane phospholipids and promote oligodendroglial pathology.
Culturally‐informed Community‐engaged Efforts to Improve Inclusion and Engagement of Underrepresented Ethnocultural Populations in the Alzheimer’s Disease Neuroimaging Initiative 3 Study: The ADNI Diversity Task Force
Okonkwo, Ozioma C. , Ashford, Miriam T. , Conti, Catherine , Strong, Jospeh, Raman, Rema , Miller, Garrett, Nosheny, Rachel L. , Coker, Godfrey, Miller, Melanie J. , Petersen, Ronald C. , Aisen, Paul S. S, Mindt, Mónica Rivera , Donohue, Michael , Aisen, Paul , Barkhof, Frederik

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S22 | Pages: No page available

10.1002/alz.075375 Get It

AbstractBackgroundEthnoculturally diverse individuals from underrepresented populations (URPs), including but not limited to Black/African American and Hispanic/Latinx adults, are disproportionally affected by Alzheimer’s disease (AD) compared to non‐Hispanic/Latinx white (NLW) adults. However, URPs have historically been under‐included in AD studies. The objective of this study is to describe efforts, and the results of those efforts, to increase enrollment and engagement of ethnoculturally diverse individuals from URPs in the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3).MethodsEfforts undertaken by ADNI to increase enrollment and engagement of URPs included (1) launching of a Diversity Taskforce (DVTF) lead by two health disparities experts in July 2020, charged with overseeing ADNI’s mission in this space. Specific DVTF activities included: (2) the establishment, funding, and instrumental support (e.g., training, consultation, resources) of diversity at 13 ADNI3 sites; (3) changing ADNI protocol to facilitate research participation of URPs (e.g., optional lumbar puncture and sharing of amyloid PET results); (4) hiring a marketing agency to launch culturally‐informed digital/social media campaigns for the 13 DVTF Sites, with local websites; (5) development of a database to capture performance metrics of inclusion efforts at the 13 DVTF Sites; and (6) formation of a six‐member External Advisory Board, comprised of leaders in health disparities research, to guide DVTF efforts.ResultURP enrollment at these 13 DVTF sites improved from 1.1 URPs per month previously to >4 URPs per month, a 264% increase. Across all 59 ADNI sites, overall enrollment of ethnoculturally diverse individuals from URPs went from 89 (16.8%) to 126 (21.1%), representing a 25% increase in enrollment between May 2020 and September 2021. Moreover, since February 1st, 2021, ADNI enrolled 43 new participants of which 33 (77%) were from URPs.ConclusionIt is possible to improve the enrollment and retention of URPs in AD research using a multi‐pronged community engaged approach that also provides human capital, infrastructure, and financial resources. The success of the DVTF has led to the formation of a new Engagement Core in ADNI4, tasked with implementing a scaled‐up culturally‐informed, community‐engaged research approach to URP inclusion and retention across all 59 ADNI sites.
The impact of Alzheimer’s disease pathology and cardiovascular risk factors on cross‐sectional brain structure in the U.S. POINTER Imaging study
Ward, Tyler J. , Lovato, Laura, Snyder, Heather M. , DeCarli, Charles , Jagust, William J. , Landau, Susan, Group, the U.S. POINTER Study, Harrison, Theresa M. , Lockhart, Samuel N. , Vemuri, Prashanthi , Baker, Laura D. , Koeppe, Robert A. , Group, the U.S. POINTER Study

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.079145 Get It

AbstractBackgroundThe U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial to evaluate the effect of lifestyle interventions in cognitively unimpaired older adults (60‐79 years) at risk for decline/dementia. Here, using data from the POINTER Imaging ancillary substudy, we explore how Alzheimer’s disease pathology and cardiovascular risk influence brain structure, cognition and their relationship.MethodPOINTER Imaging participants underwent cross‐sectional MRI, [18F]Florbetaben (FBB) Aβ‐PET and [18F]MK6240 tau‐PET. FBB and MK6240 data were processed using previously validated methods. MRIs were processed with voxel‐based morphometry. To quantify cardiovascular risk, the Framingham risk score (FRS) was calculated for each participant. We used linear regression models in the whole sample as well as in Aβ status subgroups to evaluate voxel‐wise associations of brain structure, measured using voxel‐based morphometry, with age, FRS, AD pathology (cortical summary Aβ and entorhinal cortex (ERC) tau burden), and a global cognition composite score.ResultAcross all 624 participants (Table 1), cognition (age‐adjusted) was positively related to brain structure across temporal, frontal and medial parietal cortices (Fig. 1A). ERC tau‐PET was negatively associated with brain structure in bilateral medial temporal lobes (MTL) and, notably, in bilateral basal forebrain (Fig. 1B). FRS showed significant negative associations in superior temporal gyrus and occipital cortex (Fig. 1C), but tau‐PET associations remained similar when adjusting for FRS. In Aβ+ participants, cognition‐ and FRS‐structure relationships were weaker but tau‐PET‐structure associations were stronger and extended outside the MTL. In Aβ‐ participants, cognition‐ and FRS‐structure relationships were similar to those observed in the whole cohort and tau‐PET associations were no longer significant.ConclusionIn this heterogeneous cohort of older adults, tau was associated with brain structure in strikingly specific patterns that were related to Aβ but not to cardiovascular risk as measured by the FRS. Tau‐structure associations were restricted to temporal lobes and basal forebrain and were independent of more widespread cognition‐structure associations, indicating that factors other than tau may play a critical role. Our next steps include comparing the current cohort to others with different at‐risk characteristics (e.g., ADNI, Berkeley Aging Cohort Study).
Nonlinear and Non-Monotonic Relationship between Default Mode Network Connectivity and Hippocampal Volumes across the ADNI Cohort Cross-Sectionally and Longitudinally (P06.025)
Murphy, Mathew, Gunter, Jeff, Wiste, Heather J. , Gregg, Brain, Boeve, Bradley, Petersen, Ronald C. , Weiner, Michael W. , Jack, Clifford, Jones, David T. , Murphy, Mathew, Vemuri, Prashanthi , Knopman, David S. , Bernstein, Matt A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p06.025 Get It

Preliminary Results of the NINDS/NIBIB Consensus Meeting to Evaluate Pathological Criteria for the Diagnosis of CTE (P2.178)
McKee, Ann C. , Alvarez, Victor E., Cairns, Nigel J. , Crary, John F. , Folkerth, Rebecca D., Montine, Thomas J. , Montenigro, Philip H. , Perl, Daniel P. , Stewart, William F., Vonsattel, Jean Paul, Gordon, Wayne A., Bieniek, Kevin F. , Dams-O’Connor, Kristen , Keene, C. Dirk , Litvan, Irene , Stein, Thor D. , Stewart, William, Tripodis, Yorghos , Dickson, Dennis W.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p2.178 Get It

CTIM-33. EFFICACY AND SAFETY STUDY OF NEOADJUVANT EFINEPTAKIN ALFA (NT-I7) AND PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA
Twohy, Erin , Kizilbash, Sani H. , Ruff, Michael W. , Uhm, Joon H. , D’Andre, Stacy D. , Riviere-Cazaux, Cécile , Lee, Byung Ha , Flickinger, Lynn M. , Campian, Jian , Kizilbash, Sani H , Webb, Mason , Sener, Uğur , Burns, Terry C. , Galanis, Evanthia , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v70-v70

10.1093/neuonc/noad179.0273 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive form of brain tumor in adults. Despite maximal surgical resection, irradiation, and chemotherapy, median overall survival (OS) for recurrent GBM (rGBM) remains at only 30 weeks. GBM tumors have an immune-suppressive microenvironment with low numbers of tumor-infiltrating lymphocytes (TILs). Interleukin 7 (IL-7) plays a key role in T cell homeostasis and survival, with IL-7 inducing T cell expansion in lymphopenic conditions. Efineptakin alfa (NT-I7), a long-acting IL-7, has been shown to increase effector CD8 T cells and reduce suppressor T-regulatory cells in murine GBM models, with subsequently improved OS. We recently completed a Phase I study in newly diagnosed GBM patients which showed that NT-I7 is safe, well-tolerated, and increased absolute lymphocyte counts (ALCs), and determined maximum tolerated dose for Phase II. We hypothesized that NT-I7 may not only mitigate GBM treatment-associated immune suppression, but also potentiate the effect of immune checkpoint blockade, leading to an increase in TILs and improved survival. The purpose of this study is to evaluate the safety and efficacy of combining NT-I7 and pembrolizumab in rGBM patients. This is an open-label, single arm one-stage Phase II study of NT-I7 and pembrolizumab as neoadjuvant and adjuvant therapy with surgery for adult patients with rGBM. We plan to enroll 30 evaluable patients, including a 6-patient safety run-in. The primary endpoint is the 9-month OS rate. Secondary endpoints include progression-free survival, objective response rate, changes in ALC, and adverse events profile. The correlative endpoints include studies to assess the anti-glioma immune response, changes in T cell subsets and functionality, peripheral cytokine quantification, and immunohistochemical analysis of GBM tissue. Longitudinal cerebrospinal fluid proteomics is optional. This study opened in Jan 2023. Six (6) of the planned thirty (30) patients had been enrolled by time of submission.